Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)

Brian Godman; Magdalene Wladysiuk; Stuart McTaggart; Amanj Kurdi; Eleonora Allocati; Mihajlo Jakovljevic; Francis Kalemeera; Iris Hoxha; Anna Nachtnebel; Robert Sauermann; Manfred Hinteregger; Vanda Marković-Peković; Biljana Tubic; Guenka Petrova; Konstantin Tachkov; Juraj Slabý; Radka Nejezchlebova; Iva Selke Krulichová; Ott Laius; Gisbert Selke; Irene Langner; András Harsanyi; András Inotai; Arianit Jakupi; Svens Henkuzens; Kristina Garuolienė; Jolanta Gulbinovič; Patricia Vella Bonanno; Jakub Rutkowski; Skule Ingeberg; Øyvind Melien; Ileana Mardare; Jurij Fürst; Sean Macbride-Stewart; Carol Holmes; Caridad Pontes; Corinne Zara; Marta Turu Pedrola; Mikael Hoffmann; Vasileios Kourafalos; Alice Pisana; Rita Banzi; Stephen Campbell; Bjorn Wettermark

doi:10.1155/2023/9757348

Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)

Brian Godman^*
, Magdalene Wladysiuk
, Stuart McTaggart
, Amanj Kurdi
, Eleonora Allocati
, Mihajlo Jakovljevic
, Francis Kalemeera
, Iris Hoxha
, Anna Nachtnebel
, Robert Sauermann
, Manfred Hinteregger
, Vanda Marković-Peković
, Biljana Tubic
, Guenka Petrova
, Konstantin Tachkov
, Juraj Slabý
, Radka Nejezchlebova
, Iva Selke Krulichová
, Ott Laius
, Gisbert Selke

Irene Langner, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuolienė, Jolanta Gulbinovič, Patricia Vella Bonanno, Jakub Rutkowski, Skule Ingeberg, Øyvind Melien, Ileana Mardare, Jurij Fürst, Sean Macbride-Stewart, Carol Holmes, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Mikael Hoffmann, Vasileios Kourafalos, Alice Pisana, Rita Banzi, Stephen Campbell, Bjorn Wettermark

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Comment/debate

Abstract

In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below. (Figure Presented). Figure 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.

Original language	English
Article number	9757348
Journal	BioMed Research International
Volume	2023
DOIs	https://doi.org/10.1155/2023/9757348
Publication status	Published - 2023

Access to Document

10.1155/2023/9757348

Cite this

Godman, B., Wladysiuk, M., McTaggart, S., Kurdi, A., Allocati, E., Jakovljevic, M., Kalemeera, F., Hoxha, I., Nachtnebel, A., Sauermann, R., Hinteregger, M., Marković-Peković, V., Tubic, B., Petrova, G., Tachkov, K., Slabý, J., Nejezchlebova, R., Krulichová, I. S., Laius, O., ... Wettermark, B. (2023). Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193). BioMed Research International, 2023, Article 9757348. https://doi.org/10.1155/2023/9757348

@article{5433c5675cdc4fe8aebf2fb99f3b0382,

title = "Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)",

abstract = "In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below. (Figure Presented). Figure 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a \% of total insulin glargine 100 IU/ml (DDD based) over time across Europe.",

author = "Brian Godman and Magdalene Wladysiuk and Stuart McTaggart and Amanj Kurdi and Eleonora Allocati and Mihajlo Jakovljevic and Francis Kalemeera and Iris Hoxha and Anna Nachtnebel and Robert Sauermann and Manfred Hinteregger and Vanda Markovi{\'c}-Pekovi{\'c} and Biljana Tubic and Guenka Petrova and Konstantin Tachkov and Juraj Slab{\'y} and Radka Nejezchlebova and Krulichov{\'a}, \{Iva Selke\} and Ott Laius and Gisbert Selke and Irene Langner and Andr{\'a}s Harsanyi and Andr{\'a}s Inotai and Arianit Jakupi and Svens Henkuzens and Kristina Garuolienė and Jolanta Gulbinovi{\v c} and Bonanno, \{Patricia Vella\} and Jakub Rutkowski and Skule Ingeberg and {\O}yvind Melien and Ileana Mardare and Jurij F{\"u}rst and Sean Macbride-Stewart and Carol Holmes and Caridad Pontes and Corinne Zara and Pedrola, \{Marta Turu\} and Mikael Hoffmann and Vasileios Kourafalos and Alice Pisana and Rita Banzi and Stephen Campbell and Bjorn Wettermark",

note = "Publisher Copyright: {\textcopyright} 2023 Brian Godman et al.",

year = "2023",

doi = "10.1155/2023/9757348",

language = "English",

volume = "2023",

journal = "BioMed Research International",

issn = "2314-6133",

publisher = "John Wiley and Sons Ltd",

}

Godman, B, Wladysiuk, M, McTaggart, S, Kurdi, A, Allocati, E, Jakovljevic, M, Kalemeera, F, Hoxha, I, Nachtnebel, A, Sauermann, R, Hinteregger, M, Marković-Peković, V, Tubic, B, Petrova, G, Tachkov, K, Slabý, J, Nejezchlebova, R, Krulichová, IS, Laius, O, Selke, G, Langner, I, Harsanyi, A, Inotai, A, Jakupi, A, Henkuzens, S, Garuolienė, K, Gulbinovič, J, Bonanno, PV, Rutkowski, J, Ingeberg, S, Melien, Ø, Mardare, I, Fürst, J, Macbride-Stewart, S, Holmes, C, Pontes, C, Zara, C, Pedrola, MT, Hoffmann, M, Kourafalos, V, Pisana, A, Banzi, R, Campbell, S & Wettermark, B 2023, 'Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)', BioMed Research International, vol. 2023, 9757348. https://doi.org/10.1155/2023/9757348

Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193). / Godman, Brian; Wladysiuk, Magdalene; McTaggart, Stuart et al.
In: BioMed Research International, Vol. 2023, 9757348, 2023.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)

AU - Godman, Brian

AU - Wladysiuk, Magdalene

AU - McTaggart, Stuart

AU - Kurdi, Amanj

AU - Allocati, Eleonora

AU - Jakovljevic, Mihajlo

AU - Kalemeera, Francis

AU - Hoxha, Iris

AU - Nachtnebel, Anna

AU - Sauermann, Robert

AU - Hinteregger, Manfred

AU - Marković-Peković, Vanda

AU - Tubic, Biljana

AU - Petrova, Guenka

AU - Tachkov, Konstantin

AU - Slabý, Juraj

AU - Nejezchlebova, Radka

AU - Krulichová, Iva Selke

AU - Laius, Ott

AU - Selke, Gisbert

AU - Langner, Irene

AU - Harsanyi, András

AU - Inotai, András

AU - Jakupi, Arianit

AU - Henkuzens, Svens

AU - Garuolienė, Kristina

AU - Gulbinovič, Jolanta

AU - Bonanno, Patricia Vella

AU - Rutkowski, Jakub

AU - Ingeberg, Skule

AU - Melien, Øyvind

AU - Mardare, Ileana

AU - Fürst, Jurij

AU - Macbride-Stewart, Sean

AU - Holmes, Carol

AU - Pontes, Caridad

AU - Zara, Corinne

AU - Pedrola, Marta Turu

AU - Hoffmann, Mikael

AU - Kourafalos, Vasileios

AU - Pisana, Alice

AU - Banzi, Rita

AU - Campbell, Stephen

AU - Wettermark, Bjorn

PY - 2023

Y1 - 2023

N2 - In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below. (Figure Presented). Figure 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.

AB - In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below. (Figure Presented). Figure 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.

UR - https://www.scopus.com/pages/publications/85152659616

U2 - 10.1155/2023/9757348

DO - 10.1155/2023/9757348

M3 - Comment/debate

C2 - 37065720

AN - SCOPUS:85152659616

SN - 2314-6133

VL - 2023

JO - BioMed Research International

JF - BioMed Research International

M1 - 9757348

ER -

Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this